2012年4月,美国FDA批准更新了Merck公司的非那雄胺(finasteride)1mg片剂Propecia和5mg片剂Proscar的标签,主要修订了非那雄胺的性不良反应在停药后仍可能持续相当时间(数周至数月)的研究信息。新标签指出,服用Propecia患者在停药后仍可能有性欲低下、射精问题和性高潮障碍现象;服用Proscar患者在停药后仍可能有性欲低下现象。但新标签也指出,服用Propecia或Proscar患者的不育和(或)精液质量差 In April 2012, the US FDA approved the update of Merck’s label of finasteride 1mg tablet Propecia and 5mg tablet Proscar, which mainly revised that finasteride’s sexual adverse reactions may still continue after drug withdrawal A considerable amount of time (weeks to months) of research information. The new label states that patients taking Propecia may still have hypovolemia, ejaculation problems and orgasmic disorders after discontinuation; patients who take Proscar may still have hypogonadism after discontinuation. But the new label also pointed out that patients taking Propecia or Proscar infertility and (or) poor quality of semen